Not independent
Tenure on this board
18.5 yrs
Also a director at
Xencor Inc (XNCR)
Meeting calendar
NBIX · Annual meeting · Wednesday, May 27, 2026
Neurocrine Biosciences Inc
3 nominees · 4 ballot items.
Elect three Class III directors; advisory vote on executive compensation (say-on-pay); approve amendment to 2025 Equity Incentive Plan to add 4,000,000 shares; ratify Ernst & Young LLP as independent auditor.
Market cap
$17.2B
1Y TSR
+27.8%
Board grade
C+
Record date
Mar 31, 2026
Filing
DEF 14A
Meeting concluded · May 27, 2026
Follow how the vote landed and what changed on Neurocrine Biosciences Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot4
- 1
Election of Directors
ManagementBoard: FORElect three Class III director nominees (Kevin C. Gorman, Ph.D.; Gary A. Lyons; Johanna Mercier) to serve three-year terms.
- 2
Advisory Vote on Compensation Paid to the Company’s Named Executive Officers (Say-on-Pay
ManagementBoard: FORAdvisory (non-binding) vote to approve compensation of the Company’s named executive officers as disclosed in the proxy statement.
More detail
The advisory say-on-pay proposal asks shareholders to approve, on a non-binding basis, the compensation paid to the company’s named executive officers as disclosed in the Compensation Discussion and Analysis and related tables. Management is seeking shareholder approval to reaffirm its executive compensation philosophy emphasizing pay-for-performance, with a mix of base salary, annual cash incentives tied to corporate goals, and long-term equity awards (stock options, RSUs and PRSUs). The Compensation Committee and its independent consultant evaluated market data and peer practices; the committee reports strong historical shareholder support for the program and considered ongoing stockholder engagement. The board recommends approval because it believes the program aligns NEO incentives with long-term stockholder value, maintains competitive positioning to retain talent, and includes governance features like clawbacks, limits on repricing, and ownership guidelines to mitigate risk. The vote is advisory and non-binding; management commits to consider the results in future compensation decisions. The proposal’s context includes recent strong operational performance in 2025, PRSU payouts at 125% for 2023 awards, and a CEO change in 2024; these dynamics inform the committee’s compensation decisions and rationale.
- 3
Approval of an Amendment to the Company’s 2025 Equity Incentive Plan
ManagementBoard: FORApprove amending the 2025 Equity Incentive Plan to increase shares available for issuance by 4,000,000 and increase ISO limit by same amount.
- 4
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
33.5 yrs
Also a director at
Travere Therapeutics Inc (TVTX)
Independent
Tenure on this board
5.3 yrs
Also a director at
Arcus Biosciences Inc (RCUS)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 7.2% | 7,211,843 | $950M |
| 2 | DODGE COX | 5.4% | 5,461,037 | $719M |
| 3 | AQR CAPITAL MANAGEMENT LLC | 4.8% | 4,842,396 | $638M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.7% | 4,726,344 | $623M |
| 5 | JPMORGAN CHASE CO | 4.6% | 4,602,527 | $592M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4.5% | 4,511,904 | $594M |
| 7 | STATE STREET CORP | 4.3% | 4,354,526 | $574M |
| 8 | BlackRock, Inc. | 3.3% | 3,297,831 | $434M |
| 9 | TWO SIGMA INVESTMENTS, LP | 3.0% | 3,060,570 | $403M |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 2.4% | 2,418,897 | $319M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Neurocrine Biosciences Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Jazz Pharmaceuticals PLCJAZZ
Annual meeting·Jul 23, 2026·$15.2B
Steris PLCSTE
Annual meeting·Jul 31, 2026·$21.6B
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.8B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.1B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.6B
Reference
Frequently asked questions
- When is the Neurocrine Biosciences Inc 2026 annual meeting?
- Neurocrine Biosciences Inc (NBIX) holds its 2026 annual shareholder meeting on Wednesday, May 27, 2026.
- What is the record date for the Neurocrine Biosciences Inc 2026 meeting?
- The record date for the Neurocrine Biosciences Inc 2026 meeting is Tuesday, March 31, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Neurocrine Biosciences Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Neurocrine Biosciences Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Neurocrine Biosciences Inc 2026 meeting?
- Shareholders will vote on 4 proposals at the Neurocrine Biosciences Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.